Streetbeat News

Stock Prices

SPWR

SunPower's stock trades lower following a downgrade by Guggenheim from Neutral to Sell, with a new price target set at $1.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 5:13 pm

VKTX

Traders are closely monitoring Viking Therapeutics due to circulating M&A blog comments suggesting that a large pharmaceutical company may be interested in taking over VKTX.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 5:04 pm

ALNY

Goldman Sachs downgraded Alnylam Pharmaceuticals (NASDAQ:ALNY) from its previous rating to Neutral, adjusting the price target from $230.00 to $173.00. Despite the downgrade, ALNY shares have risen by 0.41% in the last 24 hours to $148.04. The new price target suggests a potential 16.86% increase from the current price. Alnylam is recognized for its pioneering work in RNA interference (RNAi) therapeutics, with five drugs on the market and several clinical programs across different therapeutic areas.

Portfolio Pulse from Benzinga Insights

February 16, 2024 | 5:00 pm

AXL

American Axle & Manufacturing Holdings, Inc. (NYSE:AXL) reported a Q4 adjusted loss per share of $(0.09), beating estimates of a $(0.19) loss. Q4 sales rose 5% YoY to $1.46 billion, surpassing the $1.42 billion forecast. The company attributes the sales increase to volume and mix, despite the UAW work stoppage. Adjusted EBITDA for Q4 was $169.5 million, up from $157.7 million YoY. However, adjusted free cash flow decreased to $4.5 million from $99.0 million in Q4 2022. For FY24, American Axle targets sales between $6.05 billion and $6.35 billion, with adjusted EBITDA between $685 million and $750 million, expecting North American light vehicle production of about 15.8 million units. The company anticipates a gross new and incremental business backlog of approximately $600 million in future annual sales from 2024 to 2026, with an electrification mix of 50%. AXL shares dropped 1.93% to $8.385.

Portfolio Pulse from Nabaparna Bhattacharya

February 16, 2024 | 5:00 pm

PTEN

Raymond James has maintained its Strong Buy rating for Patterson-UTI Energy (NASDAQ:PTEN) but lowered its price target from $16.00 to $15.00. PTEN's shares are currently trading down at $11.71, indicating a potential 28.1% increase to the new target price. Patterson-UTI Energy operates as one of the largest land rig drilling contractors in the U.S., with operations primarily in Texas, the Appalachian region, and Colombia.

Portfolio Pulse from Benzinga Insights

February 16, 2024 | 5:00 pm

MTRN

Keybanc has reaffirmed its Overweight rating on Materion (NYSE:MTRN) and increased its price target from $140.00 to $157.00. Materion's shares are currently trading at $137.46, indicating a potential 14.22% increase to the new target price. Materion is a US-based producer of engineered materials, primarily for electronic applications.

Portfolio Pulse from Benzinga Insights

February 16, 2024 | 5:00 pm

UEIC

B. Riley Securities has maintained its Neutral rating on Universal Electronics (NASDAQ:UEIC) but raised its price target from $9.00 to $10.50. Universal Electronics' shares have fallen 6.07% in the last 24 hours to $8.35. The new price target suggests a potential 25.75% increase. Universal Electronics develops and manufactures electronic products, focusing on the subscription broadcast, consumer electronics, and residential security markets, primarily in the United States.

Portfolio Pulse from Benzinga Insights

February 16, 2024 | 5:00 pm

ANIP

Truist Securities has reaffirmed its Buy rating on ANI Pharmaceuticals (NASDAQ:ANIP), increasing its price target from $70.00 to $72.00. ANI Pharmaceuticals' shares have risen 5.87% in the last 24 hours to $60.93. The new price target suggests an 18.17% upside potential. ANI Pharmaceuticals focuses on developing, manufacturing, and marketing generic prescription pharmaceuticals, with the majority of its revenue coming from the United States.

Portfolio Pulse from Benzinga Insights

February 16, 2024 | 5:00 pm

SWAV

Shockwave Medical's shares surged following the announcement of their Q4 financial results, which exceeded expectations. Additionally, Needham reaffirmed a Buy rating on Shockwave Medical and increased its price target from $260 to $286.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 4:54 pm

TDS

Telephone And Data Systems (TDS) shares are trading lower following the release of their Q4 financial results and the issuance of FY24 guidance.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 4:52 pm